Avalo Therapeutics Inc. (NASDAQ:AVTX) saw a downside of -8.33% to close Monday at $0.11 after subtracting -$0.01 on the day. The 5-day average trading volume is 21,135,541 shares of the company’s common stock. It has gained $0.1820 in the past week and touched a new high 3 times within the past 5 days. An average of 8,076,795 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,771,216.
AVTX’s 1-month performance is -63.32% or -$0.1899 on its low of $0.1061 reached on 08/21/23. The company’s shares have touched a 52-week low of $0.11 and high of $7.00, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, AVTX has lost -97.82% or -$4.9301 and has reached a new high 4 times. However, the current price is down -98.43% from the 52-week high price.
Insider Transactions
AVTX stock investors last saw insider trading activity on Jun 27.ARMISTICE CAPITAL, LLC (10% Owner) most recently sold 937,404 shares at $0.52 per share on Jun 27. This transaction cost the insider $486,888. 10% Owner, ARMISTICE CAPITAL, LLC, sold 2,746,138 shares at a price of $0.61 on Jun 26.
Valuation Metrics
AVTX stock has a beta of 1.34. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.16.
Avalo Therapeutics Inc.’s quick ratio for the period ended June 29 was 0.30, with the current ratio over the same period at 0.30. In terms of profitability, the gross margin trailing 12 months is 85.80%. The trailing 12-month EBITDA margin is -206.49%. The firm’s gross profit as reported stood at $14.62 million against revenue of $18.05 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -58.61% to -$8.19 million, while revenue of -$9.96 million was -21.61% off the previous quarter. Analysts expected AVTX to announce -$0.8 per share in earnings in its latest quarter, but it posted -$0.59, representing a 26.30% surprise. EBITDA for the quarter stood at more than -$6.76 million. AVTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 31.2 million, with total debt at $16.19 million. Shareholders hold equity totaling $20.25 million.
Let’s look briefly at Avalo Therapeutics Inc. (AVTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 23.72% to suggest the stock is trending oversold, with historical volatility in this time period at 150.44%.
The stock’s 5-day moving average is $0.1290, reflecting a -15.38% or -$0.0200 change from its current price. AVTX is currently trading -56.61% above its 20-day SMA, -93.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -97.35% and SMA200 by-98.35%.
Stochastic %K and %D was 15.81% and 17.54% and the average true range (ATR) pointed at 0.0358. The RSI (14) points at 26.51%, while the 14-day stochastic is at 3.72% with the period’s ATR at 0.0656. The stock’s 9-day MACD Oscillator is pointing at -0.0078 and -0.0244 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Avalo Therapeutics Inc. (NASDAQ: AVTX), RBC Capital Mkts launched coverage with an Outperform rating. Analysts offering their rating for AVTX stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate AVTX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is AVTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $0.75 and a high of $0.75, with their median price target at $0.75. Looking at these predictions, the average price target given by analysts is for Avalo Therapeutics Inc. (AVTX) stock is $0.75.
